Lee Seeyoun, Yoo Jun-Il, Lee Young-Kyun, Park Jung-Wee, Won Seokhyung, Yeom Jiung, Im Jin Woo, Lim Seok Min, Ha Yong-Chan, Koo Kyung-Hoi
Department of Surgery, Center for Breast Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Department of Orthopaedic Surgery, Gyeongsang National University Hospital, Jinju, Korea.
J Bone Metab. 2020 Feb;27(1):27-34. doi: 10.11005/jbm.2020.27.1.27. Epub 2020 Feb 29.
The fracture risk induced by anti-estrogen therapy in patients with breast cancer remains controversial. The aim of this study was to perform a meta-analysis and systematic review to evaluate the risk of osteoporotic fracture in patients with breast cancer.
A systematic search was performed to identify studies that included any osteoporotic fracture (hip fracture and vertebral fracture) in patients breast cancer. Main outcome measures were occurrence and risk of osteoporotic fractures including hip and vertebral fractures in patients and controls.
A systematic search yielded a total of 4 studies that included osteoporotic fracture outcomes in patients with breast cancer. Meta-analysis showed a higher risk of osteoporotic fracture in patients with breast cancer. Analysis of these 4 studies involving a total of 127,722 (23,821 cases and 103,901 controls) patients showed that the incidence of osteoporotic fractures was higher in the breast cancer group than in the control group. The pooled estimate of crude relative risk for osteoporotic fracture was 1.35 (95% confidence interval, 1.29-1.42; <0.001).
Although studies were limited by a small number, results suggested a possible association between anti-estrogen therapy and increased risk of osteoporotic fractures in patients with breast cancer.
抗雌激素治疗对乳腺癌患者造成的骨折风险仍存在争议。本研究旨在进行一项荟萃分析和系统评价，以评估乳腺癌患者发生骨质疏松性骨折的风险。
进行系统检索，以确定纳入乳腺癌患者任何骨质疏松性骨折（髋部骨折和椎体骨折）的研究。主要结局指标为患者和对照中骨质疏松性骨折（包括髋部和椎体骨折）的发生率和风险。
系统检索共获得4项纳入乳腺癌患者骨质疏松性骨折结局的研究。荟萃分析显示，乳腺癌患者发生骨质疏松性骨折的风险更高。对这4项共涉及127,722例患者（23,821例病例和103,901例对照）的研究分析表明，乳腺癌组骨质疏松性骨折的发生率高于对照组。骨质疏松性骨折的粗相对风险合并估计值为1.35（95%置信区间，1.29 - 1.42；P < 0.001）。
尽管研究数量有限，但结果提示抗雌激素治疗与乳腺癌患者骨质疏松性骨折风险增加之间可能存在关联。
